The Prognostic and Therapeutic Potential of CTLA-4 in Hematological Malignancies.

According to the recent literature, CTLA-4 is overexpressed in different HMs which is correlated with poor survival, while is associated with better prognosis in Chronic Lymphocytic Leukemia (CLL). Targeting CTLA-4 in Acute Myeloid Leukemia (AML), Sezary Syndrome (SS), Hodgkin's Lymphoma (HL), etc. is helpful. While is not recommended and may even be harmful in multiple myeloma (MM) and CLL. Also, it seems that certain CTLA-4 gene polymorphisms are efficient factors in the course of HMs. Future studies may broaden our knowledge regarding the role of CTLA-4 in HMs.